COEP Coeptis Therapeutics, Inc.
USHealthcareAs of 2026-07-02 15:59
Why COEP matters now
Coeptis Therapeutics, Inc. (COEP) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.99 with -8.57% on the session and $38.6M in market capitalization; recent performance reads 1-month +70.18% and YTD +14.53%.
The latest financial table shown here is Q1 2026, with revenue of $113.8K, net income of $-4.0M, and EPS of $-0.65. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -13.9%.
The latest indexable market news headline is "Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes BSG Series CM, LLC filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.73
P/S
40.56
EV/EBITDA
-4.80
DCF Value
$3.20
FCF Yield
-13.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.2%
Operating Margin
-912.4%
Net Margin
-839.7%
ROE
-89.6%
ROA
-60.0%
ROIC
-71.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $113.8K | $-4.0M | $-0.65 |
| Q4 2025 | $862.0K | $-1.6M | $-0.29 |
| FY 2025 | $1.4M | $-11.9M | $-2.81 |
| Q3 2025 | $237.4K | $-2.7M | $-0.58 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.43
Coeptis Therapeutics, Inc. is a biopharmaceutical company dedicated to the advancement and market introduction of both generic and proprietary pharmaceutical products, as well as cell therapy platforms, specifically for individuals battling cancer. Their current portfolio includes CD38-GEAR-NK, a Vy-Gen drug formulated to combat CD38-positive cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Complementing this, they offer CD38-Diagnostic, an in vitro screening tool designed to pinpoint which cancer patients would most likely benefit from specific anti-CD38 monoclonal antibody therapies. Beyond their core oncology focus, Coeptis has forged alliances, notably with Statera BioPharma for the development and market launch of STAT-201, intended for Crohn's disease. They also hold joint development and ownership rights for CPT60621, a potential treatment for Parkinson's Disease, through a collaboration with Vici Health Sciences, LLC. Established in 2017, Coeptis Therapeutics, Inc. is headquartered in Wexford, Pennsylvania.